Loading
Life sciences · Journal article
International Journal of Drug Delivery Technology · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cancer remains a major global health challenge, with conventional therapies limited by toxicity, drug resistance, and accessibility issues.Itrifal Aftimoon, a classical Unani polyherbal formulation from the National Formulary of Unani Medicine, contains twelve botanical and mineral ingredients including Triphala (Terminalia chebula, Emblica officinalis, Terminalia belerica), Plumbago zeylanica, Cuscuta reflexa, and Cassia angustifolia.These herbs provide diverse phytochemicals gallic acid, ellagic acid, plumbagin, flavonoids, and polyphenols enabling multi-targeted anticancer mechanisms.Gupta et al. (2022) demonstrated that Itrifal-e-Aftimoon potentiates imatinib's anti-leukemic effects in chronic myeloid leukemia by modulating FAK/STAT/Akt/ERK signaling pathways.The formulation exhibits antioxidant activity via Nrf2-ARE activation, anti-inflammatory effects through NF-κB and COX-2 suppression, immunomodulation enhancing natural killer cells, and selective cytotoxicity against cancer cells while sparing normal cells.Preclinical studies show tumor growth inhibition and improved survival in animal models.Clinical observations suggest enhanced quality of life and reduced chemotherapy toxicities, though rigorous trials are limited.Toxicological studies indicate favourable safety profiles with high therapeutic margins, though drug interactions require monitoring.Future research priorities include randomized controlled trials, pharmacokinetic studies, standardization protocols, bioactive compound identification, and nanoformulation development for improved bioavailability.Integrating traditional Unani knowledge with modern pharmaceutical sciences offers opportunities for evidence-based cancer therapeutics that address current oncological challenges while providing safer, accessible treatment options globally.